TRLV
Rating neutralAI MemoPost-earnings T+1Trulieve Cannabis
As of 2026-08-08/Post-earnings T+1/Confidence medium
Data freshness
AI Memo
As of 2026-08-08 • Model: RankAlpha Sentiment Codex
Decision Panel
Action, confidence, horizon, and decision blockers at a glance.
Action
neutral
Confidence
medium
Horizon
—
Key catalyst
Share repurchase authorization • 2026-08-07
Base target: $10 / p=55% prob
Biggest risk
Revenue and adjusted EBITDA declined year over year, Q2 revenue fell sequentially despite prior growth expectations, and cash flow was weaker than the prior-year quarter. The large Harvest deconsolidation loss complicates comparability, while CEO open-market selling adds secondary caution. No verified post-print analyst revisions or target changes are available.
Invalidation
Break below $7 or thesis failure.
What would change my mind?
Trulieve remains adjusted-profitable with a 60% gross margin, $98 million of adjusted EBITDA, $53 million of quarterly operating cash flow, $32 million of free cash flow, and $325 million of cash. The buyback and potential regulatory or state-market expansion could support a rerating.
Research note
Recommendation
neutral
Confidence
medium
As of
2026-08-08
Base target
$10
p=55%
Bull target
$12
p=20%
Bear target
$7
p=25%
Key bullets
Fast scan of bull, bear, and watch items
BullKey bullets
- Mixed Q2 print creates near-term reset
- Rescheduling and market-expansion optionality
- Trulieve remains adjusted-profitable with a 60% gross margin, $98 million of adjusted EBITDA, $53 million of quarterly operating cash flow, $32 million of free cash flow, and $325 million of cash.
BearKey bullets
- CEO Kim Rivers reported approximately 1.699 million open-market shares sold for approximately $14.7 million during June 17-26.
- [#SEC-FORM4-2026-06-22] [#SEC-FORM4-2026-06-25] [#SEC-FORM4-2026-06-26]
- Low coverage and unavailable analyst-count, revision, and consensus data limit confidence in valuation and earnings-surprise interpretation.
WatchKey bullets
- Share repurchase authorization
Summary
High-level snapshot
Recommendation
neutral
Model confidence
medium
Timeframe
-
Asset
Equity
Trigger
Post-earnings T+1
Base case: $10 (p=55%)
Target spread vs base: +26% / -32%
Scenario probabilities
Bull Target: $12 (p=20%)Base Target: $10 (p=55%)Bear Target: $7 (p=25%)
Commentary
The post-earnings signal is mixed: primary company reporting confirms weaker revenue and EBITDA trends but continued adjusted profitability, cash generation, and a buyback authorization. The available market snapshot showed the shares down about 2.8% on August 7. Analyst estimate revisions, target changes, and a verified consensus surprise comparison remain unavailable. Sparse coverage, the structural Harvest change, and insider selling support a monitoring posture rather than a directional thesis.
As of 2026-08-08 • Updated bi-weekly / post-earningsSource: Internal modelMethodology
Analyst Summary
Thesis highlights from the latest analysis
Bull Case
Trulieve remains adjusted-profitable with a 60% gross margin, $98 million of adjusted EBITDA, $53 million of quarterly operating cash flow, $32 million of free cash flow, and $325 million of cash. The buyback and potential regulatory or state-market expansion could support a rerating.
Bear Case
Revenue and adjusted EBITDA declined year over year, Q2 revenue fell sequentially despite prior growth expectations, and cash flow was weaker than the prior-year quarter. The large Harvest deconsolidation loss complicates comparability, while CEO open-market selling adds secondary caution. No verified post-print analyst revisions or target changes are available.
Drivers
Scannable catalysts and supporting factors
- Mixed Q2 print creates near-term reset
- Rescheduling and market-expansion optionality
Scenarios
Bull Target (Scenario probability)
$12 / p=20% prob
Base Target (Scenario probability)
$10 / p=55% prob
Bear Target (Scenario probability)
$7 / p=25% prob
Analysis 2026-08-08 · RankAlpha Sentiment Codex
Analysis reference price unavailable. Targets are shown without scenario returns.
Sentiment & Exposure
News Sentiment (30d)
0.00
Social Sentiment (7d)
0.00
Events
Other notable items detected
- EVENT2026-08-07Share repurchase authorizationThe company announced a repurchase program for up to the lesser of $50 million or 8,495,038 subordinate voting shares, providing a potential valuation and capital-allocation support. Execution timing and actual purchases remain unconfirmed. [#8-K-2026-08-07] [#IR-2026-08-07]Prob 65.00% • Move 5.00% • Priced-in 45.00%
Short-term Catalysts
Next few weeks
- Mixed Q2 print creates near-term reset2026-08-07Q2 revenue was $271 million, down 6% sequentially and 10% year over year, versus the prior company expectation for low-single-digit sequential growth. Adjusted EBITDA was $98 million with a 36% margin, while adjusted net income remained $20 million. The $406 million GAAP loss mainly reflected a $407 million Harvest deconsolidation impact. [#SEC-8K-2026-05-07] [#8-K-2026-08-07] [#IR-2026-08-07]Prob 100% • Move -4% • Priced-in 70%
Long-term Catalysts
Months to a year
- Rescheduling and market-expansion optionality2027-08-08Management cited DEA registration applications following medical-marijuana rescheduling, Georgia program expansion, pharmacy shipments, and broader expansion opportunities including Texas. Benefits remain conditional on regulatory implementation, demand, and execution. [#SEC-8K-2026-05-07] [#IR-2026-08-07]Prob 45% • Move 18% • Priced-in 35%
Risks
- CEO Kim Rivers reported approximately 1.699 million open-market shares sold for approximately $14.7 million during June 17-26. [#SEC-FORM4-2026-06-22] [#SEC-FORM4-2026-06-25] [#SEC-FORM4-2026-06-26]
- Low coverage and unavailable analyst-count, revision, and consensus data limit confidence in valuation and earnings-surprise interpretation.
- Q2 included a $406 million net loss and $407 million Harvest deconsolidation impact, increasing reporting and valuation volatility. [#IR-2026-08-07]
- Quarterly operating cash flow was $53 million versus $86 million in the prior-year quarter, and free cash flow was $32 million versus $75 million.
- Rescheduling, DEA registration, Georgia expansion, pharmacy distribution, and potential Texas growth remain execution- and regulatory-dependent.
- Revenue fell 10% year over year and 6% sequentially; adjusted EBITDA fell 11% year over year.
Peers
No peer data
Sources
Internal and external references used in this analysis
- Model source: RankAlpha Sentiment Codex
- Analysis date: 2026-08-08